Background — Pharma Company C

The biggest blind spot in MR training: the gap between "training was delivered" and "knowledge actually improved." Most pharma companies tracked only completion rates, with no system to verify whether MRs truly mastered new drug information. Inaccurate detailing to physicians risks credibility loss and regulatory violations.

Solution — Pharma Company C

Introduced regular product assessments for MRs, targeting Kirkpatrick Level 2 (Learning: did knowledge and skills actually improve?). Assessment results were analyzed by department and role to inform content planning, with auto-recommended remediation content for weak areas. The core model combined lunchtime microlearning with periodic quizzes.

Results — Pharma Company C

Of 107 companies, ~25–30 have Kirkpatrick Level 2 data. As assessment data accumulated, MR competency levels became visible, and HRD content planning shifted from intuition to data-driven decision-making.

Level 2 Kirkpatrick Achieved

Regular Product Test Execution

25-30 firms Level 2 Confirmed Firms

Insight — Pharma Company C

In the Kirkpatrick pyramid reality, Level 1 (reaction) data is automatically collected by 40+ companies, but fewer than 5 hold Level 4 (results) data. Reaching Level 2 at a pharma is the first answer to executives' demand to "prove the effect of training." It is the entry point to the P5 pattern, where test data becomes the foundation for content planning and capability diagnostics.

Assessment & Testing Data Analytics Personalized Recommendations